New Jersey-based healthcare communications agency Rarity Health announced on Monday that it has been named an agency finalist for the 21st MM+M Rare Disease Agency of the Year.
MM+M, first published in 1966 as Medical Marketing + Media, is a pharmaceutical industry media brand. It will announce the winner of the Rare Disease Agency of the Year in October.
Welcoming the news, Rob Newland, Rarity Health managing partner, said: "Over the past several years, we at Rarity Health have sharpened our focus on serving a diverse array of rare disease communities through our valued clients in the pharmaceutical sector. As we prepare to celebrate our 40th anniversary in 2025, we are proud to reflect on four decades of dedication to the rare disease communities we have served. This milestone is a testament to our long-standing commitment to advocacy, education and delivering critical support for patients, caregivers and healthcare professionals."
GenScript Biotech Corporation names new board members
Alchemab Therapeutics names new CEO
Breg names new chief executive officer and chief financial officer
Rivus Pharmaceuticals names new CFO and independent member of board of directors